191 related articles for article (PubMed ID: 32472705)
21. Successful dupilumab treatment for ichthyotic and atopic features of Netherton syndrome.
Murase C; Takeichi T; Taki T; Yoshikawa T; Suzuki A; Ogi T; Suga Y; Akiyama M
J Dermatol Sci; 2021 May; 102(2):126-129. PubMed ID: 33773888
[No Abstract] [Full Text] [Related]
22. Netherton Syndrome in a Mother and Her Two Children.
DeMoss J; Cooper L; Felts C; Wittenberg G
S D Med; 2022 Dec; 75(12):554-556. PubMed ID: 36893349
[TBL] [Abstract][Full Text] [Related]
23. Novel splice site mutation at the C-terminal of SPINK5 cause a unique Netherton syndrome phenotype mimicking pustular psoriasis.
Hua S; Liu J; Fang B; Qian Q; Zhang J
J Eur Acad Dermatol Venereol; 2023 Jan; 37(1):e113-e115. PubMed ID: 36165187
[No Abstract] [Full Text] [Related]
24. Ichthyosis linearis circumflexa with bamboo hair: challenges in the diagnosis and management.
Dev T; Raman Kumar M; Sethuraman G
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28554884
[TBL] [Abstract][Full Text] [Related]
25. Multidimensional response of Dupilumab in a child affected by Netherton syndrome: Improvement of trichorrhexis invaginata.
Mastrorilli C; Ambrogio F; La Torre F; Foti C; Bonamonte D; Serio C; Cardinale F
Pediatr Allergy Immunol; 2023 Jul; 34(7):e13997. PubMed ID: 37492914
[No Abstract] [Full Text] [Related]
26. Ustekinumab therapy for Netherton syndrome.
Samuelov L; Shehadeh W; Sarig O; Gat A; Matz H; Sprecher E
J Dermatol; 2023 Apr; 50(4):494-499. PubMed ID: 36419401
[TBL] [Abstract][Full Text] [Related]
27. Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.
Walker AL; Denis A; Bingham RP; Bouillot A; Edgar EV; Ferrie A; Holmes DS; Laroze A; Liddle J; Fouchet MH; Moquette A; Nassau P; Pearce AC; Polyakova O; Smith KJ; Thomas P; Thorpe JH; Trottet L; Wang Y; Hovnanian A
Bioorg Med Chem Lett; 2019 Oct; 29(20):126675. PubMed ID: 31521475
[TBL] [Abstract][Full Text] [Related]
28. Netherton syndrome previously misdiagnosed as hyper IgE syndrome caused by a probable mutation in SPINK5 C.
Özyurt K; Atasoy M; Ertaş R; Ulaş Y; Akkuş MR; Kiraz A; Hennies HC
Turk J Pediatr; 2019; 61(4):604-607. PubMed ID: 31990481
[TBL] [Abstract][Full Text] [Related]
29. A Novel SPINK5 Gene Mutation Associated with Netherton Syndrome in an Omani Patient.
Hamza N; Al Sukaiti N; Ahmed KAM; Romano R; Gokhale UA; Pan-Hammarström Q
Sultan Qaboos Univ Med J; 2021 Nov; 21(4):652-656. PubMed ID: 34888090
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab improves clinical symptoms in children with Netherton syndrome by suppressing Th2-mediated inflammation.
Yan S; Wu X; Jiang J; Yu S; Fang X; Yang H; Bai X; Wang H; Luo X
Front Immunol; 2022; 13():1054422. PubMed ID: 36569942
[TBL] [Abstract][Full Text] [Related]
31. Establishment of an induced pluripotent stem cell line (SAHGMUi001-A) from a patient with Netherton syndrome carrying SPINK5 mutation.
Xu M; Wang L; Yin J; Xiong J; Guo Q; Yang W
Stem Cell Res; 2021 Mar; 51():102213. PubMed ID: 33556917
[TBL] [Abstract][Full Text] [Related]
32. Long-term dupilumab therapy in Netherton syndrome with severe atopic manifestations: Case report and review of the literature.
Özkaya E; Günay MB; Babuna Kobaner G; Keskinkaya Z; Gökalp MO
Australas J Dermatol; 2023 May; 64(2):272-277. PubMed ID: 36745433
[TBL] [Abstract][Full Text] [Related]
33. Netherton syndrome caused by compound heterozygous mutation, c.80A>G mutation in SPINK5 and large-sized genomic deletion mutation, and successful treatment of intravenous immunoglobulin.
Zhang Z; Pan C; Wei R; Li H; Yang Y; Chen J; Li M; Yao Z
Mol Genet Genomic Med; 2021 Mar; 9(3):e1600. PubMed ID: 33452875
[TBL] [Abstract][Full Text] [Related]
34. Hair abnormality in Netherton syndrome observed under polarized light microscopy.
Utsumi D; Yasuda M; Amano H; Suga Y; Seishima M; Takahashi K
J Am Acad Dermatol; 2020 Sep; 83(3):847-853. PubMed ID: 32029302
[TBL] [Abstract][Full Text] [Related]
35. Severe lethal phenotype of a Japanese case of Netherton syndrome with homozygous founder mutations of SPINK5 c.375_376delAT.
Itoh K; Kako T; Suzuki N; Sakurai N; Sugiyama K; Yamanishi K
J Dermatol; 2015 Dec; 42(12):1212-4. PubMed ID: 26365906
[No Abstract] [Full Text] [Related]
36. Netherton Syndrome: A Genotype-Phenotype Review.
Sarri CA; Roussaki-Schulze A; Vasilopoulos Y; Zafiriou E; Patsatsi A; Stamatis C; Gidarokosta P; Sotiriadis D; Sarafidou T; Mamuris Z
Mol Diagn Ther; 2017 Apr; 21(2):137-152. PubMed ID: 27905021
[TBL] [Abstract][Full Text] [Related]
37. Netherton Syndrome: Insights into Pathogenesis and Clinical Implications.
Chiticariu E; Hohl D
J Invest Dermatol; 2020 Jun; 140(6):1129-1130. PubMed ID: 32446331
[TBL] [Abstract][Full Text] [Related]
38. Secukinumab for Netherton syndrome: a Malaysian experience.
Ting IPL; Lee TS; Teo HG; Albela H; Tang MM; Leong KF
Clin Exp Dermatol; 2023 Nov; 48(12):1366-1369. PubMed ID: 37503742
[No Abstract] [Full Text] [Related]
39. A novel SPINK5 mutation and successful subcutaneous immunoglobulin replacement therapy in a child with Netherton syndrome.
Zelieskova M; Banovcin P; Kozar M; Kozarova A; Nudzajova Z; Jesenak M
Pediatr Dermatol; 2020 Nov; 37(6):1202-1204. PubMed ID: 32767583
[TBL] [Abstract][Full Text] [Related]
40. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
